The 60th annual American Society of Hematology (ASH) conference just wrapped up in San Diego and the high-profile conference didn’t disappoint. Many studies caught our eye at the conference, but data from three trials in particular stood-out for their potential to ignite investor optimism. In this episode of The Motley Fool’s Industry Focus: Healthcare, host Shannon Jones is joined by Motley Fool contributor Todd Campbell to discuss:
How Celgene (NASDAQ: CELG) can profit from pivoting its CAR-T program;
Why bispecific antibodies could be the next big thing in in cancer treatment;
What was behind Global Blood Therapeutics (NASDAQ: GBT) skyrocketing, post-presentation share price.
Subscribe to The Motley Fool’s YouTube Channel:
Or, follow our Google+ page:
Inside The Motley Fool: Check out our Culture Blog!
Join our Facebook community:
Follow The Motley Fool on Twitter: